GB899011A - Rubeola vaccine and process - Google Patents
Rubeola vaccine and processInfo
- Publication number
- GB899011A GB899011A GB5115/59A GB511559A GB899011A GB 899011 A GB899011 A GB 899011A GB 5115/59 A GB5115/59 A GB 5115/59A GB 511559 A GB511559 A GB 511559A GB 899011 A GB899011 A GB 899011A
- Authority
- GB
- United Kingdom
- Prior art keywords
- virus
- medium
- rays
- preferred
- cultures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18451—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A rubeola (measles) virus vaccine is produced by growing measles virus on monkey (i.e. any primate except man or lemurs) renal cell cultures, harvesting the live virus therefrom in a parenterally acceptable vehicle and destroying the infective capacity of the virus. The preferred cell culture is that of renal cells from African vervet monkeys (Cercopithecus lalandi). Those from rhesus, cynomolgus and squirrel monkeys and those of simians, e.g. chimpanzee and baboons, may be used if substantially free from competitive latent viruses. Propogation is by any well known tissue culture technique, e.g. Maitland minced tissue method, submerged culture of suspended cells or cultures of cells grown on glass (preferred). Any complete tissue culture nutrient medium may be used, e.g. "medium 199," Eagles medium, medium NCTC 107 which may advantageously include about 5% to 10% of a filtered mamalian serum, e.g. calf serum (preferred). The medium may also contain agents to prevent bacterial or mycotic growth, e.g. penicillin, streptomycin, mycostatin, parabens. The cultures are incubated at about 25 DEG to 40 DEG C. (preferably 32 DEG to 38 DEG C.) for about 5 to 12 days and the virus is then harvested in a parenterally acceptable medium, e.g. those mentioned above, one of, these being used to replace the growth medium if unsuitable (e.g. contains mammalian serum). Cellular debris is removed by centrifugation and the virus is inactivated by conventional means, e.g. by chemicals, e.g. formaldehyde, b -propiolactone, mustard oils or chlorine or by forms of physical energy, e.g. heat (45 DEG C. for 30 hours or 25 DEG C. for 200 hours), ultra-violet radiation, ionizing radiations (preferred), e.g. a -rays, cathode-rays, b -rays, g -rays or protons, the virus being present in variable conditions, e.g. in liquid or frozen suspensions, as a lyophilised powder in bulk or in sealed containers, e.g. of glass or low density polythene. Preservatives, e.g. benzethenium chloride, parabens or "Merthiolate" (Registered Trade Mark) may be added to the final vaccine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72136458A | 1958-03-14 | 1958-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB899011A true GB899011A (en) | 1962-06-20 |
Family
ID=24897679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB5115/59A Expired GB899011A (en) | 1958-03-14 | 1959-02-13 | Rubeola vaccine and process |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB899011A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3186908A (en) * | 1962-08-16 | 1965-06-01 | Parke Davis & Co | Calcium lactobionate stabilization of labile antigenic virus vaccine materials |
WO2015011265A1 (en) * | 2013-07-26 | 2015-01-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for inactivating viruses using electron beams |
-
1959
- 1959-02-13 GB GB5115/59A patent/GB899011A/en not_active Expired
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3186908A (en) * | 1962-08-16 | 1965-06-01 | Parke Davis & Co | Calcium lactobionate stabilization of labile antigenic virus vaccine materials |
WO2015011265A1 (en) * | 2013-07-26 | 2015-01-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for inactivating viruses using electron beams |
CN105431171A (en) * | 2013-07-26 | 2016-03-23 | 弗劳恩霍弗促进应用研究注册公司 | Method for inactivating viruses using electron beams |
US10080795B2 (en) | 2013-07-26 | 2018-09-25 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for inactivating viruses using electron beams |
US10881724B2 (en) | 2013-07-26 | 2021-01-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for inactivating viruses using electron beams |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rowe et al. | Characterization of a factor formed in the course of adenovirus infection of tissue cultures causing detachment of cells from glass | |
RU94046296A (en) | METHODS FOR PRODUCING A VACCINE, METHOD OF CULTIVATION OF CELLS, COMPOSITION | |
Epstein et al. | Histocompatibility typing and course of canine venereal tumors transplanted into unmodified random dogs | |
Sykes et al. | Observations on a cell line producing mammary tumor virus | |
Lee et al. | Human astrovirus serotypes | |
Baron et al. | New maintenance medium for cell culture | |
Fahmy et al. | Mutagenicity of 2-chloroethyl methanesulphonate in Drosophila melanogaster | |
GB899011A (en) | Rubeola vaccine and process | |
Gravell et al. | Viruses and renal carcinoma of Rana pipiens: IX. The influence of temperature and host cell on replication of frog polyhedral cytoplasmic deoxyribovirus (PCDV) | |
US4169761A (en) | Process for the cultivation of viruses | |
Melnick et al. | Stabilized Suspensions of Monkey Kidney Cells Suitable for Intercontinental Shipment. | |
Hollaender et al. | X. Modification of Radiation Damage After Exposure to X Rays | |
Harvey | Note on the Absorption of Organic Phosphorus Compounds by NitzschiaClosterium in the Dark | |
Band | Biotin, a growth requirement for four soil amoebae | |
Shimura et al. | Extracellular release of photosynthetic products by a pelagic blue-green alga, Trichodesmium thiebautii | |
GB1492930A (en) | Virus growth | |
ATE322540T1 (en) | PREPARATION FOR TRANSFER OF ACTIVE TUMOR-SPECIFIC IMMUNIZATION FROM AN IMMUNIZED ALLOGENEIC BONE MARROW DONOR | |
CN110305792A (en) | A method of the separation micro- frosting microorganism of soil | |
Goldner et al. | Immunity against a transplantable ascites tumor of spontaneous origin in an inbred rat strain | |
Lapin | Epidemiology of leukemia among baboons of Sukhumi monkey colony | |
Gibbs et al. | Preliminary experiments to determine which host ribosomes are used by some further plant viruses | |
Mefferd Jr et al. | Influence of temperature upon radiation sensitivity of thermophilic and mesophilic bacteria | |
Buchner et al. | Infectious hepatitis and the cytological response in embryonated eggs | |
US3629470A (en) | Process for purification of animal rna viruses | |
Heath | A constitutive enzyme system for glucose transport by Chlorella sorokiniana |